Dracen Pharmaceuticals announces two presentations at the American...
Data support that sirpiglenastat (DRP-104) has therapeutic potential in targeting KEAP1-mutant lung cancer as well as squamous cell carcinoma of the head and neck(PRWeb April 08, 2022)Read the full story at https://www.prweb.com/releases/2022/4/prweb18601225.htm
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Head and Neck Cancer | Lung Cancer | Pharmaceuticals | Skin Cancer | Squamous Cell Carcinoma